RayzeBio
Defeating cancers with radiopharmaceutical medicines
RayzeBio, a Bristol Myers Squibb Company, is a dynamic clinical-stage radiopharmaceutical therapeutics (RPT) company headquartered in San Diego, CA. The company – which operates as a standalone entity within BMS – has an industry-leading position in actinium-based RPTs, a pipeline of potentially first-in-class and best-in-class drug programs, and a state-of-the-art manufacturing facility.
Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. RayzeBio is focused on improving the survival of people with cancer by harnessing the power of targeted radioisotopes. The company is developing innovative drugs against targets of solid tumors, potentially offering benefits for patients in safety and efficacy.
RayzeBio has two locations:
- An R&D Center of Excellence in San Diego, CA, equipped with full in vitro biological capabilities and internal small molecule and peptide chemistry
- A state-of-the-art research and manufacturing facility in Indianapolis, IN, to allow for end-to-end drug development and commercial production.
With the backing and support of Bristol Myers Squibb, RayzeBio has a vision to become the world’s leader in radiopharmaceutical therapeutics, one of the most promising new modalities for the treatment of cancer.
Science
We are focused on purposeful discovery, development and manufacturing of innovative radiopharmaceutical therapeutics (RPTs) for solid tumors.
RPT is positioned to a core modality in cancer treatment – with the potential to be combined across other modalities. This treatment has the advantage of being both diagnostic and therapeutic, and may offer advantages in efficacy and safety. RayzeBio is at the forefront of pioneering the application of RPTs using an alpha-emitting isotope, Ac225.
We expect to generate several therapeutic candidates by leveraging critical capabilities, infrastructure, and dedicated manufacturing facility.
Pipeline
With the backing of BMS, and the drive of a biotechnology company, we are focused on efficiently delivering for patients. We are focused on targets with a high expression in significant tumors and have created a pipeline of multiple drug and development candidates in therapeutic areas with significant market opportunities.
RayzeBio programs leverage Ac225, an alpha emitter. Alpha emitters are the next-generation of therapeutic radionuclides. Due to higher potency, Ac225 may enhance RPT results, enabling efficacy in tumors with lower target expression and overcoming resistance to beta radiation. Alpha particles deliver up to 400 times higher energy compared to beta particles, leading to double-stranded DNA breaks which are lethal to cancer cells.
RayzeBio Leadership Team
An entrepreneurial team with a shared vision to build the leading radiopharmaceutical company.
Ben Hickey
Abhi Bhat, PhD
Eric Bischoff
Stephen Carter, PhD
Nicole Greene
Megan Humphreys
Amreen Husain, MD
Kathie Huynh
Kevin Rosenthal
Nicholas Smith, PhD
Careers at RayzeBio
You will be directed to the BMS job application portal. RayzeBio is a BMS company.
Manufacturing
Support every area of production on an industrial scale to ensure our medicines are safe, effective, and of high-quality for patient use.
Research & Development
Contribute to our initial discovery and development of new drugs and solutions, including preclinical testing and clinical trials.
Clinical Operations
Plan, manage and execute clinical trials and research studies to evaluate the safety and efficacy of new drugs and treatment protocols.
Quality
Monitor the delivery of high-quality products through attentive compliance to quality assurance, testing and quality control.
Radiopharma
Drive the innovative science behind our radiopharmaceutical products, which have the unique advantage of being both diagnostic and therapeutic.
Supporting Functions
Provide essential support to RayzeBio through core functions, including: finance, accounting, and commercial operations.
RayzeBio locations
San Diego, CA
Our state-of-the-art 28,000 sq. ft. radiopharmaceutical research facility enables us to carry out all aspects for discovery of novel drug candidates. This center of excellence includes:
- Radiochemistry labeling lab for alpha and beta radioisotopes
- Vivarium with molecular imaging and biodistribution analysis
- Full in-vitro biological characterization
- Small molecule and peptide chemistry capabilities
- DMPK suite
Indianapolis, IN
Our 77,000 sq. ft. specialized manufacturing facility in Indianapolis, IN is a first-of-its-kind, allowing for the production of isotope and manufacture of therapeutic drugs in a fully integrated process. Our facility has a central location in the United States, allowing for ground shipments to a large number of cities within two days of manufacture.
You will be directed to the BMS job application portal.
RayzeBio is a BMS company.
Career Stories
At RayzeBio, we are committed to fostering a supportive and innovative environment where your professional aspirations can thrive. Our employees are at the heart of our success, and their stories reflect the passion and dedication that drive our mission forward.
Hear from our people and learn why they chose RayzeBio for their careers.
Join our Talent Community
Your career can have meaning. Your work can change lives. Join our talent community today so we can stay in touch about our uniquely interesting career opportunities. This is where transformations happen.
English 
Japanese 
French 
German 
Italian 
Korean 
Portuguese 
Chinese (China) 
Spanish 
Chinese (Taiwan) 
